1stOncology™: Cancer Intelligence Service – Page 10009 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Trovagene to Present New Clinical Data for Onvansertib in Metastatic KRAS-Mutated Colorectal Cancer at ASCO 2020 Gastrointestinal Cancers Symposium

On January 21, 2020 Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing onvansertib for the treatment of various cancers including colorectal, prostate and leukemia, reported that a poster featuring safety and efficacy data from its Phase 1b/2 study in metastatic KRAS-mutated colorectal cancer (mCRC), will be presented on Saturday, January 25th, 2020 at the American Society for Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2020 Gastrointestinal Cancers Symposium in San Francisco (Press release, Trovagene, JAN 21, 2020, View Source [SID1234553368]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The poster presentation will be available for download from the Scientific Presentations page on the Trovagene website at View Source
Details of the Poster Presentation are as follows:
Title: A Phase 1b/2 Study of Onvansertib in Combination with FOLFIRI and Bevacizumab for Second-Line Treatment of Metastatic Colorectal Cancer (mCRC) in Patients with a KRAS Mutation
Session: Trials in Progress Poster Session C: Anal and Colorectal Cancer
Abstract: TP5265
Poster: M21
Date/Time and Location: Saturday, January 25th, 6:30 AM – 7:55 AM – Moscone Convention Center Level 1, West Hall

About the Phase 1b/2 Trial of Onvansertib in Metastatic KRAS-mutated Colorectal Cancer
The trial, A Phase 1b/2 Study of Onvansertib (PCM-075) in Combination with FOLFIRI and Bevacizumab for Second‑Line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS Mutation (NCT03829410), will evaluate the safety and efficacy of onvansertib in combination with standard-of-care FOLFIRI and Avastin (bevacizumab). Up to 44 patients, with a confirmed KRAS mutation, metastatic and unresectable disease, who have failed or are intolerant of treatment with FOLFOX (fluoropyrimidine and oxaliplatin) with or without Avastin (bevacizumab), will be enrolled. The trial is being conducted at two prestigious cancer centers: USC Norris Comprehensive Cancer Center and The Mayo Clinic Arizona.
About Onvansertib
Onvansertib is a first-in-class, third-generation, oral and highly-selective adenosine triphosphate (ATP) competitive inhibitor of the serine/threonine polo-like-kinase 1 (PLK1) enzyme, which is over-expressed in multiple cancers including leukemias, lymphomas and solid tumors. Onvansertib targets the PLK1 isoform only (not PLK2 or PLK3), is orally administered and has a 24-hour half-life with only mild-to-moderate side effects reported. Trovagene believes that targeting only PLK1 and having a favorable safety and tolerability profile, along with an improved dose/scheduling regimen will significantly improve on the outcome observed in previous studies with a former panPLK inhibitor in AML.

Trovagene Inc. | 11055 Flintkote Avenue | San Diego | CA 92121 | Tel.: USA [+1] 888-391-7992

Onvansertib has demonstrated synergy in preclinical studies with numerous chemotherapies and targeted therapeutics used to treat leukemias, lymphomas and solid tumor cancers, including irinotecan, FLT3 and HDAC inhibitors, taxanes and cytotoxins. Trovagene believes the combination of onvansertib with other compounds has the potential to improve clinical efficacy in acute myeloid leukemia (AML), metastatic castration-resistant prostate cancer (mCRPC), non-Hodgkin lymphoma (NHL), colorectal cancer and triple-negative breast cancer (TNBC), as well as other types of cancer.
Trovagene has three ongoing clinical trials of onvansertib: A Phase 2 trial of onvansertib in combination with Zytiga (abiraterone acetate)/prednisone in patients with mCRPC who are showing signs of early progressive disease (rise in PSA but minimally symptomatic or asymptomatic) while currently receiving Zytiga (NCT03414034); a Phase 1b/2 Study of onvansertib in combination with FOLFIRI and Avastin for second-line treatment in patients with mCRC with a KRAS mutation (NCT03829410); and a Phase 1b/2 clinical trial of onvansertib in combination with low-dose cytarabine or decitabine in patients with relapsed or refractory AML (NCT03303339). Onvansertib has been granted orphan drug designation by the FDA in the U.S. and by the EC in the European Union for the treatment of patients with AML.
Trovagene licensed onvansertib (also known as NMS-1286937 and PCM-075) from Nerviano Medical Sciences (NMS), the largest oncology-focused research and development company in Italy, and a leader in protein kinase drug development. NMS has an excellent track record of licensing innovative drugs to pharma/biotech companies, including Array (recently acquired by Pfizer), Ignyta (acquired by Roche) and Genentech.

Sirona Biochem Announces Grant of Stock Options

On January 21, 2020 Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB)(US-OTC: SRBCF)("Sirona" or the "Company") reported that it has granted an aggregate of 6,800,000 incentive stock options to management, independent directors and consultants of the Company (Press release, Sirona Biochem, JAN 21, 2020, View Source [SID1234553367]). The options, to purchase common shares in the capital of the Company at a price of $0.45 per common share, will be for periods ranging from 1 to 10 years. The options have been granted under the terms of the Company’s stock option plan.

Quest Diagnostics Named One of 2020 "World’s Most Admired Companies" by FORTUNE Magazine for Sixth Consecutive Year

On January 21, 2020 Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, reported that it has been selected as one of FORTUNE’s World’s Most Admired Companies in 2020 for the sixth consecutive year (Press release, Quest Diagnostics, JAN 21, 2020, View Source [SID1234553366]).

The annual survey designated Quest Diagnostics as one of only five companies to attain Most Admired status in the "Health Care: Pharmacy and Other Services" industry category.

"This award belongs to our 46,000 employees who are committed to creating a healthier world every day," said Steve Rusckowski, Chairman, President and CEO. "We are honored to receive this award for the sixth consecutive year."

FORTUNE’s "World’s Most Admired Companies" list is based on surveys of 680 companies from 30 countries, asking executives, directors, and analysts to rate enterprises within their own industry on nine criteria, from investment value and quality of management and products to social responsibility and ability to attract talent. A company’s score had to rank in the top half of its industry peer group to be listed.

Orion Biotechnology Acquires Exclusive License to University of Geneva Novel Drug Discovery Platform

On January 21, 2020 Orion Biotechnology Canada Ltd., a clinical stage biotechnology company, reported that it has executed a definitive agreement with the University of Geneva for an exclusive global license to a novel drug discovery platform for the generation of G protein coupled receptor (GPCR) chemokine analogs (Press release, Orion Biotechnology, JAN 21, 2020, View Source [SID1234553365]).

The proprietary platform was developed by Dr. Oliver Hartley and his team at the University of Geneva to facilitate the rapid and low cost identification, optimization, and generation of novel chemokine analog peptide drug candidates. Orion Biotechnology’s initial focus will be on the GPCR superfamily of chemokine receptors, building on technology and know-how accumulated by Dr. Hartley’s team.The chemokine – chemokine receptor system plays a central role in immunology, for both the maintenance of a healthy immune system and in response to infection. At the same time, perturbation of the chemokine-chemokine receptor system is associated with numerous serious diseases, including cancer, infectious diseases, inflammation, and neurological disease such as multiple sclerosis.

Mark Groper, President and CEO of Orion Biotechnology said "We are very excited about using this unique technology platform to discover new drug candidates targeting therapeutically important chemokine receptors. We believe leveraging this proprietary platform will reduce the cost and timelines required for generating new chemokine analogs by a factor of ten. In addition to adding to our development pipeline, these valuable new assets can be licensed to other parties with an R&D interest in chemokine targets. Chemokine analogs have key advantages as a drug class and, with this platform, we intend to position ourselves as the go-to provider for other pharmaceutical companies pursuing chemokine targets."

The terms of the license include a Collaboration Agreement for Orion and the University of Geneva to work together to develop new peptide drug candidates moving forward. Dr. Raluca Flükiger, Licensing Officer at the University of Geneva Technology Transfer Office (Unitec), added, "We are delighted to have concluded this agreement with Orion Biotechnology, which we hope will enable the full potential of this technology to be realized. Through ongoing collaboration with Orion, the University’s goal is to facilitate the development of new therapies for currently untreatable diseases. In addition, we are optimistic that the molecules discovered using this platform will stimulate research towards better understanding of the biology and pharmacology of chemokine receptors."

Chi-Med Announces Proposed Public Offering of ADSs

On January 21, 2020 Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) reported that it intends to offer US$110 million of American Depositary Shares ("ADSs"), each representing five ordinary shares, par value US$0.10 each of Chi-Med, on the Nasdaq Global Select Market ("Offering") (Press release, Hutchison China MediTech, JAN 21, 2020, https://www.chi-med.com/chi-med-announces-proposed-public-offering-of-adss/ [SID1234553364]). Chi-Med intends to grant the underwriters a 30-day option to purchase up to an aggregate of US$16.5 million of additional ADSs at the public offering price, less underwriting discounts and commissions. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or final terms of the Offering. The price for the Offering has not yet been determined.

Chi-Med will receive all of the net proceeds from the sale of ADSs in the Offering, if completed, which it intends to use primarily to fund its ongoing research and clinical development efforts and expand its commercialization capabilities.

Details of the final terms of the Offering will be determined following the bookbuilding process.

BofA Securities, Inc., Goldman Sachs (Asia) L.L.C. and Morgan Stanley & Co. LLC (in alphabetical order) are acting as joint global coordinators and joint bookrunners for the Offering.

Chi-Med’s directors intend that the Offering would be effected within existing allotment authorities and pre-emption disapplications granted pursuant to shareholder resolutions passed at Chi-Med’s annual general meeting held on April 24, 2019. The Offering would therefore not be conditional upon shareholder approval.

Shareholders and potential investors should note that the proposed Offering may or may not proceed and are accordingly advised to exercise caution when dealing in the securities of Chi-Med.